西妥珠单抗抑制伊布替尼治疗的慢性淋巴细胞白血病中Wnt5a诱导的Rac1活化
研究探讨伊布替尼治疗的慢性淋巴细胞白血病(CLL)患者中Rac1活化及Wnt5a的作用。发现伊布替尼治疗患者的CLL细胞仍存在Rac1活化,Wnt5a可诱导Rac1活化并促进增殖,而抗ROR1单抗西妥珠单抗(UC-961)可阻断该过程。体内实验显示西妥珠单抗联合伊布替尼清除白血病细胞的效果显著优于任一单药。
要点
- 伊布替尼治疗的CLL患者CLL细胞中Rac1仍处于活化状态。
- Wnt5a可诱导经伊布替尼处理的CLL细胞Rac1活化并增强增殖。
- 西妥珠单抗联合伊布替尼在体内清除白血病细胞效果显著优于单药。
核心结论
- 西妥珠单抗可能增强伊布替尼治疗CLL或其他ROR1阳性B细胞恶性肿瘤的活性。
研究设计与样本
- 研究分析伊布替尼治疗的CLL患者CLL细胞中Rac1活化状态,并体外评估Wnt5a诱导的Rac1活化及增殖,以及西妥珠单抗(UC-961)的阻断作用。
- 进行体内实验比较西妥珠单抗联合伊布替尼与任一单药清除白血病细胞的效果。
主要发现
- 接受伊布替尼治疗的CLL患者CLL细胞中Rac1处于活化状态。
- 在完全抑制BTK和BCR信号的有效浓度下,Wnt5a仍可诱导经伊布替尼处理的CLL细胞Rac1活化并增强增殖。
- 西妥珠单抗(UC-961)可阻断Wnt5a诱导的Rac1活化。
- 体内实验中,西妥珠单抗联合伊布替尼清除白血病细胞的效果显著优于任一单药。
关键数值与推荐
- 西妥珠单抗(UC-961)为抗ROR1单克隆抗体。
- 伊布替尼为Bruton酪氨酸激酶(BTK)抑制剂,可阻断BCR信号。
- ROR1为Wnt5a的受体,Wnt5a可促进Rac1活化。
临床怎么用
- 作者认为西妥珠单抗可能增强伊布替尼治疗CLL或其他ROR1阳性B细胞恶性肿瘤患者的活性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK) that can block BCR-signaling. However, ibrutinib cannot induce complete responses (CR) or durable remissions without continued therapy, suggesting alternative pathways also contribute to CLL growth/survival that are independent of BCR-signaling. ROR1 is a receptor for Wnt5a, which can promote activation of Rac1 to enhance CLL-cell proliferation and survival. In this study, we found that CLL cells of patients treated with ibrutinib had activated Rac1. Moreover, Wnt5a could induce Rac1 activation and enhance proliferation of CLL cells treated with ibrutinib at concentrations that were effective in completely inhibiting BTK and BCR-signaling. Wnt5a-induced Rac1 activation could be blocked by cirmtuzumab (UC-961), an anti-ROR1 mAb. We found that treatment with cirmtuzumab and ibrutinib was significantly more effective than treatment with either agent alone in clearing leukemia cells in vivo. This study indicates that cirmtuzumab may enhance the activity of ibrutinib in the treatment of patients with CLL or other ROR1+ B-cell malignancies.
引用
- Yu J, Chen L, Cui B, et al. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia. 2016. PMID: 27904138. doi:10.1038/leu.2016.368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。